Signature of circulating microRNAs in patients with acute heart failure

Our aim was to identify circulating microRNAs (miRNAs) associated with acute heart failure (AHF).

[1]  Dingli Xu,et al.  A subset of circulating microRNAs is expressed differently in patients with myocardial infarction. , 2015, Molecular medicine reports.

[2]  B. Karadağ,et al.  The prognostic value of circulating microRNAs in heart failure: preliminary results from a genome-wide expression study , 2015, Journal of cardiovascular medicine.

[3]  Jenny P. C. Chong,et al.  Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction , 2015, European journal of heart failure.

[4]  P. van der Harst,et al.  HFpEF vs. HFrEF: can microRNAs advance the diagnosis? , 2015, European journal of heart failure.

[5]  T. Thum,et al.  MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure , 2015, European journal of heart failure.

[6]  Gary D Bader,et al.  Systems analysis reveals down-regulation of a network of pro-survival miRNAs drives the apoptotic response in dilated cardiomyopathy. , 2015, Molecular bioSystems.

[7]  Xiao-Ming Gao,et al.  Therapeutic silencing of miR‐652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  G. Nickenig,et al.  MicroRNA Expression in Circulating Microvesicles Predicts Cardiovascular Events in Patients With Coronary Artery Disease , 2014, Journal of the American Heart Association.

[9]  V. Cameron,et al.  Circulating miR-323-3p and miR-652: candidate markers for the presence and progression of acute coronary syndromes. , 2014, International journal of cardiology.

[10]  M. Jeong,et al.  miR-18a-5p MicroRNA Increases Vascular Smooth Muscle Cell Differentiation by Downregulating Syndecan4 , 2014, Korean circulation journal.

[11]  Naoto Tsuchiya,et al.  Circulating Exosomal microRNAs as Biomarkers of Colon Cancer , 2014, PloS one.

[12]  M. Latronico,et al.  Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. , 2014, Journal of the American College of Cardiology.

[13]  M. Latronico,et al.  Circulating miR-29 a , Among Other Up-Regulated MicroRNAs , Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients With Hypertrophic Cardiomyopathy , 2014 .

[14]  G. Paolisso,et al.  Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non‐responders , 2013, European journal of heart failure.

[15]  Q. Shan,et al.  Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure. , 2013, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[16]  V. Cameron,et al.  Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients , 2013, European journal of heart failure.

[17]  Karen S. Frese,et al.  Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. , 2013, European heart journal.

[18]  Elizabeth A. McClellan,et al.  The hypoxia-inducible microRNA cluster miR-199a∼214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation. , 2013, Cell metabolism.

[19]  Y. Devaux,et al.  A Panel of 4 microRNAs Facilitates the Prediction of Left Ventricular Contractility after Acute Myocardial Infarction , 2013, PloS one.

[20]  Shengshou Hu,et al.  Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation , 2013, Journal of Cardiothoracic Surgery.

[21]  Yanjie Lu,et al.  MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. , 2013, The Journal of clinical investigation.

[22]  Jinqiao Qian,et al.  Nebivolol Induces Distinct Changes in Profibrosis MicroRNA Expression Compared With Atenolol, in Salt-Sensitive Hypertensive Rats , 2013, Hypertension.

[23]  L. Zentilin,et al.  Functional screening identifies miRNAs inducing cardiac regeneration , 2012, Nature.

[24]  Barbara Burwinkel,et al.  Extracellular miRNAs: the mystery of their origin and function. , 2012, Trends in biochemical sciences.

[25]  Danish Sayed,et al.  GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. , 2012, Cardiovascular research.

[26]  Offer Amir,et al.  Serum levels of microRNAs in patients with heart failure , 2012, European journal of heart failure.

[27]  T. Thum,et al.  A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. , 2012, Journal of molecular and cellular cardiology.

[28]  S. Fichtlscherer,et al.  Transcoronary Concentration Gradients of Circulating MicroRNAs , 2011, Circulation.

[29]  J. Epstein,et al.  MicroRNA-processing Enzyme Dicer Is Required in Epicardium for Coronary Vasculature Development* , 2011, The Journal of Biological Chemistry.

[30]  Liza S. M. Wong,et al.  Telomere Length of Circulating Leukocyte Subpopulations and Buccal Cells in Patients with Ischemic Heart Failure and Their Offspring , 2011, PloS one.

[31]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[32]  H. Nonogi,et al.  Assessment of plasma miRNAs in congestive heart failure. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[33]  Jan A Staessen,et al.  Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.

[34]  Qing Jing,et al.  MicroRNAs are dynamically regulated in hypertrophic hearts, and miR‐199a is essential for the maintenance of cell size in cardiomyocytes , 2010, Journal of cellular physiology.

[35]  F. Crea,et al.  MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. , 2010, Physiological genomics.

[36]  Perry D Moerland,et al.  MiR423-5p As a Circulating Biomarker for Heart Failure , 2010, Circulation research.

[37]  Joseph A. Hill,et al.  MicroRNAs and heart failure diagnosis: MiR-acle or MiR-age? , 2010, Circulation research.

[38]  D. J. Veldhuisen,et al.  Effects of alagebrium, an advanced glycation end‐product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial , 2010, European journal of heart failure.

[39]  P. Ponikowski,et al.  Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. , 2010, Journal of cardiac failure.

[40]  Frank D Sistare,et al.  Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. , 2009, Clinical chemistry.

[41]  H. Hillege,et al.  Cardiac Resynchronization Therapy Improves Renal Function , 2009 .

[42]  Michael D. Schneider,et al.  Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure , 2008, Proceedings of the National Academy of Sciences.

[43]  Jian-Fu Chen,et al.  Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. , 2007, Journal of molecular and cellular cardiology.

[44]  Michael T. McManus,et al.  Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2 , 2007, Cell.

[45]  Tiny Jaarsma,et al.  Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure , 2004, European journal of heart failure.

[46]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.